Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
abbvie
4
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
4
×
detroit blog main
detroit top stories
4
×
gilead sciences
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
clinical trials
deals
multiple myeloma
startups
alzheimer's disease
amgen
astrazeneca
biogen
cancer immunotherapy
What
bio
roundup
acquisitions
ceo
daniel
drug
gilead
o’day
sciences
american
announced
annual
approval
ash
biggest
biogen’s
biopharmaceutical
blood
borne
build
buy
cancers
collabs
companies
company’s
conference
convo
covid
deal
debut
diego
dyne’s
earlier
failures
gathering
gilead’s
guide
help
hematology
host
Language
unset
Current search:
photo
×
cancer
×
" detroit top stories "
×
novartis
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More